Navigation Links
Many Heart Attack Patients Don't Get Best Emergency Treatment
Date:8/19/2007

oplasty or treatment with fibrinolytic (clot-busting) medications.

But it's those details that reveal the troubling gap between the number of patients who could have received the treatments, and those who actually did.

"We may never be able to get to 100 percent, but 10 percent of eligible patients going untreated is still too many," says first author Brahmajee Nallamothu, M.D., MPH, assistant professor of cardiovascular medicine at the U-M Medical School. "We hope our study highlights the opportunities to improve care and particularly some of the "at-risk" subgroups still less likely to receive reperfusion therapy despite eligibility, so that we can focus our clinical efforts on them."

Adds senior author Harlan Krumholz, M.D., S.M., "This study has good and bad news. We have definitely made progress in treating appropriate patients, but our findings indicate that we need to improve further to be sure that no patient who could benefit from this treatment is missed." Krumholz is the Harold H. Hines, Jr. Professor of Medicine in the Section of Cardiovascular Medicine and director of the Yale-New Haven Hospital Center for Outcomes Research and Evaluation.

The study was funded by the National Heart, Lung and Blood Institute of the National Institutes of Health. Genentech, Inc. provided the researchers access to the registry, which it sponsors.

To track the changes in acute (emergency) reperfusion therapy over time, the researchers divided the study data into three time periods: June 1994 through May 1997, June 1997 through May 2000, and June 2000 through May 2003.

The rise in emergency angioplasty was fastest from the first time period to the second; the rate of increase leveled off from the second time period to the third. Correspondingly, the number of patients receiving medication-based reperfusion dropped over the study period.

This is an appropriate shift, says Nallamothu: shifting patients from clot-busting medications to
'/>"/>

SOURCE University of Michigan Health System

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Intercept Pharmaceuticals, Inc. ... biopharmaceutical company focused on the development and commercialization of ... such as primary biliary cirrhosis, today announced that ... Executive Officer, will present at the Deutsche Bank Securities ... on Wednesday, May 29, 2013 at 4:10 ...
(Date:5/23/2013)... May 23, 2013  MedVantx, Inc., the company that ... channel announced today the Company has completed a major ... in pharmaceutical products and the upgrade of its systems ... facilities in its specialty home delivery pharmacy in ... leading pharmaceutical manufacturers, physicians, health systems and payors novel ...
(Date:5/23/2013)... 23, 2013 InspireMD, Inc. ... leader in embolic protection stents, today announced new ... ST Elevation Reperfusion) trial demonstrating that the MGuard ... drug eluting stents in all-cause mortality in ST ... the trial were presented at the InspireMD STEMI ...
Breaking Medicine Technology:MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... May 18, 2011 Ovid, part of ... the delivery of customizable electronic research information for the medical, scientific, ... OvidMD , the first clinical ... provides quick answers to clinical questions based on relevant full-text content ...
... FRANCISCO, May 18, 2011 Bayer HealthCare Pharmaceuticals, Inc. and ... that data evaluating the use of Nexavar® (sorafenib) tablets will ... Meeting of the American Society of Clinical Oncology (ASCO), June ... committed to researching the potential utility of sorafenib, and the ...
Cached Medicine Technology:Ovid Announces its First Clinical Tool, OvidMD, Designed for Physicians and Other Clinicians 2Ovid Announces its First Clinical Tool, OvidMD, Designed for Physicians and Other Clinicians 3Ovid Announces its First Clinical Tool, OvidMD, Designed for Physicians and Other Clinicians 4Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 2Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 3Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 4Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 5Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 6Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 7
(Date:5/23/2013)... OAK BROOK, Ill. (May 23, 2013) Aortic arch ... a strong independent predictor of disease of the vessels ... new study published in the June issue the journal ... the aortic arch provides functional information about vessel compliance ... disease down the road," said Kevin S. King, M.D., ...
(Date:5/23/2013)... May 23, 2013 During pregnancy both ... are affected by medical treatments, especially medication. In ... Journal of Medicine prompted the FDA to warn about ... birth defects such as persistent pulmonary hypertension and other ... serotonin reuptake inhibitor (SSRI) drugs. SSRI antidepressants are ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 Maintaining ... today launches its Summer Health Campaign. Kicking off in ... to offering a luxury bed for everyone and to ... overall health and well-being. , May is Better Sleep ... by the Better Sleep Council due to the Centers ...
(Date:5/23/2013)... To kick off barbecue season, fire up the grill ... calories with simple tips from Retrofit weight loss . ... summer. , “The powerful heat of the grill can be ... are not mindful of your selections, it can be as ... Amy Margulies. , Margulies advises clients to choose healthy options ...
(Date:5/23/2013)... 2013 Retül University , the ... announce the formation of a strategic educational partnership with ... to offer a bike industry first “Positioned for Speed” ... for time trial, road and triathlon bike fit. , ... bike fitters with a Retül University, F.I.S.T. or S.I.C.I ...
Breaking Medicine News(10 mins):Health News:MRI-based measurement helps predict vascular disease in the brain 2Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 2Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 3Health News:DUXIANA®, Quality Bed Innovator, Celebrates Better Sleep Month and Launches Summer Health Campaign 2Health News:Fire It Up! Master Calories at the Grill with Retrofit Weight Loss 2Health News:Fire It Up! Master Calories at the Grill with Retrofit Weight Loss 3Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 2Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 3
... WASHINGTON , Feb. 5 In response ... today, the American Veterinary Medical Association (AVMA) is reaffirming its ... help maintain and improve the health of U.S. livestock. , ... creating a new strategy for animal disease traceability. This comes ...
... says benefits still outweigh dangers , FRIDAY, Feb. 5 ... controversial multiple sclerosis drug Tysabri, the U.S. Food and ... a new warning on the drug,s label. , In ... FDA warned that the risk of developing progressive multifocal ...
... , TROY, Mich. , ... technology (IT) and web products and services company serving U.S. ... M. Hanley to the newly formed position of vice ... http://www.newscom.com/cgi-bin/prnh/20100205/DE50447 ) , "I am delighted to have Colleen join ...
... , , ... Diseases (HTDS; http://www.htdsmedical.com/ ) brings attention to a certain previously released ... , Dec 15, 2009 January 12,2010 , and ... for the company as all of these events are now starting to ...
... unhealthy cycle, some moms-to-be may need special support, researchers ... whose mothers were depressed during pregnancy are at increased ... suggests. , The British researchers also found that women ... years are more likely to become depressed during pregnancy, ...
... , MILWAUKEE , ... Daytona Bike Week, hundreds of female motorcycle enthusiasts and Harley-Davidson ... Association (MDA) and their efforts to find a cure for ... MDA and the Motor Company will host the 3rd Annual ...
Cached Medicine News:Health News:AVMA Calls for Stronger Animal Disease Traceability System 2Health News:More Doses of MS Drug Raise Risk of Brain Infection 2Health News:More Doses of MS Drug Raise Risk of Brain Infection 3Health News:CareTech Solutions Names Colleen M. Hanley Vice President of Marketing, Communications and Government Affairs 2Health News:CareTech Solutions Names Colleen M. Hanley Vice President of Marketing, Communications and Government Affairs 3Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 2Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 3Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 5Health News:Women Riders to Rev for a Cure at Daytona Bike Week 2Health News:Women Riders to Rev for a Cure at Daytona Bike Week 3
... Positionable Penile Prosthesis,The ... prosthesis is made of ... core strength that gives ... most: ease of positioning, ...
... The AMS 700 Series is an advanced ... in the abdomen, a pump placed in the ... the corpora cavernosa. It closely simulates the look ... standard for innovative penile implant technology, the AMS ...
... advanced three-part inflatable prosthesis consisting of a reservoir ... the scrotum and a pair of cylinders inserted ... look and performance of a natural erection. The ... AMS 700 Series now features the new Tactile ...
... Freedom leg bags are part of ... versatile line of leg bags, kits, ... varied needs of our customers. These ... sizes, and constructed of 100% latex-free ...
Medicine Products: